FierceBiotech Radio with Editas Medicine's Katrine Bosley

Editas Medicine CEO Katrine Bosley

Editas Medicine CEO Katrine Bosley, one of FierceBiotech's 2010 Top Women in Biotech, joins FierceBiotech Radio to discuss gene editing, the Biogen alumni network and life in biotech's boomtown.

Download the episode on iTunes or Stitcher, or listen below--and be sure to subscribe. Let us know what you think by dropping a line to [email protected] And if you missed past episodes of the show, you can find them here.

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.